Compass Analyst Ratings
Compass Point Downgrades MidCap Financial Investment to Neutral From Buy With $16 Price Target
Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating
Compass Therapeutics Analyst Ratings
Compass Point Remains a Buy on HCI Group (HCI)
FTAI Aviation (FTAI) Receives a Buy From Compass Point
Kepler Capital Remains a Hold on Compass (COMP)
Macerich (MAC) Receives a Buy From Compass Point
Compass Therapeutics Analyst Ratings
Iris Energy (IREN) Receives a New Rating From Compass Point
Compass Therapeutics: A Buy Rating on Promising Pipeline and Solid Financials
Compass Analyst Ratings
Buy Rating Affirmed for Compass Therapeutics on Strong Financials and Promising Clinical Trials
Compass Point Adjusts Truist Financial's Price Target to $43 From $42
Compass Pathways Analyst Ratings
Buy Rating Affirmed for COMPASS Pathways Amid Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)
Compass Analyst Ratings
Analysts Are Neutral on Top Materials Stocks: Compass Minerals International (CMP), Iluka Resources Limited (ILKAF)
Buy Rating Maintained for Compass Amid Real Estate Market Uncertainty: McTernan's Optimistic Outlook